On May 9, the Department of Health and Human Services’ (HHS’) Office of the Assistant Secretary for Preparedness and Response announced an allocation plan for the drug remdesivir, after an initial shipment was sent to seven states. The allocation comes from a donation by Gilead Sciences Inc. to the U.S. government.
The Food and Drug Administration on May 1 issued an emergency use authorization (EUA) for remdesivir, the investigational antiviral drug, for treatment of suspected or lab-confirmed COVID-19 in adults and children hospitalized with severe disease. Severe disease is defined as patients with low blood oxygen levels or those needing oxygen therapy or more intensive breathing support, such as a ventilator.
Hospitals interested in administering the donated experimental drug should contact their state health department. HHS notes that “state and local health departments have the greatest insight into community-level needs in the COVID-19 response, including appropriate distribution of a treatment in limited supply.”
Visit the America’s Essential Hospitals coronavirus resource page for more information about the outbreak.
Contact Senior Director of Policy Erin O’Malley at email@example.com or 202.585.0127 with questions.